Abstract
Angiostatin inhibits angiogenesis and metastatic tumor growth; however, its usefulness in treating primary nonmetastasizing tumors is less well understood. We now report the effectiveness of human angiostatin administration in a mouse hemangioendothelioma model. Human angiostatin was administered to mice with s.c. hemangioendothelioma and associated disseminated intravascular coagulopathy (Kasabach-Merritt syndrome). Angiostatin significantly reduced tumor volume in comparison to nontreated controls, increased survival, and prevented the profound thrombocytopenia and anemia of Kasabach-Merritt syndrome. Apoptosis of tumor cells was induced by angiostatin, but tumor cell proliferation was not inhibited. These data suggest angiostatin as a novel treatment for nonmetastasizing vascular tumors and for Kasabach-Merrit syndrome.
Original language | English (US) |
---|---|
Pages (from-to) | 5277-5280 |
Number of pages | 4 |
Journal | Cancer Research |
Volume | 57 |
Issue number | 23 |
State | Published - Dec 1 1997 |
ASJC Scopus subject areas
- Oncology
- Cancer Research